MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

MDT

95.6

+0.46%↑

VEEV

290.6

+2.46%↑

145.15

+0.79%↑

HQY

95.89

+3.35%↑

TLRY

1.52

-5%↓

Начало・Списък с акции・Ocular Therapeutix Inc

Ocular Therapeutix Inc

Отворен

СекторЗдравеопазване

11.71 -1.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.6

Максимум

12.21

Ключови измерители
By Trading Economics
Приходи	-3.8M -68M
Продажби	2.8M 13M
Марж на печалбата	-503.856
Служители	274
EBITDA	146K -64M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+75.93% upside

Дивиденти
By Dow Jones
Следващи печалби	13.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	544M 2.5B
Предишно отваряне	13.55
Предишно затваряне	11.71

Настроения в новините

By Acuity

67%

33%

326 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

6.97 / 7.62 Подкрепа & съпротива

Ocular Therapeutix Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Takaichi's Policy Steps -- Market Talk

20.10.2025 г., 23:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

20.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Dip-Buying Interest -- Market Talk

20.10.2025 г., 22:14 ч. UTC

Пазарно говорене

Zions Management Confident $50M Charge Was Isolated Event -- Market Talk

20.10.2025 г., 22:00 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire May Have Left $50 Billion on Table. Apple Stock Hit a Record. -- Barrons.com

20.10.2025 г., 21:49 ч. UTC

Придобивния, сливания и поглъщания

Kering Sells Beauty Business to L'Oréal. Everyone but This Company Wins. -- Barrons.com

20.10.2025 г., 20:56 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Encouraging Demand Drivers of Manufacturing Onshoring, Infrastructure Program Funding, Lower Interest Rates, Increasing Regionalization of Supply Chains in U.S. >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Expect to Benefit From Stronger Demand Across Platforms, Including Aluminum Flat Rolled Products, as We Move Into 2026 >STLD

20.10.2025 г., 20:38 ч. UTC

Печалби

Steel Dynamics: Some Order Hesitancy From Flat Rolled Steel Customers Due to Domestic Trade Actions >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Continue to Observe Some Customer Inventory Overhang of Value-Added Flat Rolled Products That Were Imported Earlier This Yr >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: View U.S. Intl Trade Commission's Final Determinations on Coated Flat Rolled Steel as a Significant Positive Development >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Discussions With Customers Reinforce the Increasing Importance of Low-Carbon, U.S.-Made Steel and Aluminum, Positioning Our Businesses for a Long-Term Competitive Advantage >STLD

20.10.2025 г., 20:36 ч. UTC

Печалби

Steel Dynamics: Improving Market Conditions, Including Increased Trade Stability and Favorable Interest Rate Environment, Will Contribute to Strong Domestic Demand for Steel and Aluminum >STLD

20.10.2025 г., 20:16 ч. UTC

Пазарно говорене

Canada Labor-Market Indicators Lean Dovish -- Market Talk

20.10.2025 г., 20:05 ч. UTC

Печалби

GE Aerospace Earnings Are on Tap. After the Turnaround, Investors Wonder What's Next. -- Barrons.com

20.10.2025 г., 19:39 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Industrials Post Positive Earnings. 3 Stocks Whose Charts Say 'Buy.' -- Barrons.com

20.10.2025 г., 19:34 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Jump on Colder Weather Outlook -- Market Talk

20.10.2025 г., 19:32 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Oversupply Concerns -- Market Talk

20.10.2025 г., 19:00 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More -- Barrons.com

20.10.2025 г., 18:29 ч. UTC

Пазарно говорене

Apple Sitting on Best Long-Term Product Roadmap in Years -- Market Talk

20.10.2025 г., 18:11 ч. UTC

Пазарно говорене

Economic Vital Signs Missing in Bank of Canada Survey -- Market Talk

20.10.2025 г., 18:04 ч. UTC

Пазарно говорене

Uncertainty Remains Top Concern Among Canada Firms -- Market Talk

20.10.2025 г., 17:03 ч. UTC

Пазарно говорене

Weak Demand Signals Narrower Profit Margins For Canada Firms -- Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.10.2025 г., 17:01 ч. UTC

Пазарно говорене

Bank of Canada Surveys Present Shaky Economic Outlook -- Market Talk

20.10.2025 г., 16:43 ч. UTC

Пазарно говорене

Canada Public-Sector Workers Fret Most On Labor-Market Weakness -- Market Talk

20.10.2025 г., 16:25 ч. UTC

Пазарно говорене

U.S. Natural Gas Extends Rebound on Weather Outlook -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocular Therapeutix Inc Прогноза

Ценова цел

By TipRanks

75.93% нагоре

12-месечна прогноза

Среден 20.83 USD 75.93%

Висок 31 USD

Нисък 14 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocular Therapeutix Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Ocular Therapeutix Inc през последните 3 месеца.

Техническа оценка

By Trading Central

6.97 / 7.62Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Настроение

By Acuity

326 / 371 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocular Therapeutix Inc

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.